New drug aims to outsmart Chemotherapy-Resistant ovarian cancer
NCT ID NCT07708753
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This phase 3 trial tests an experimental drug called SYS6043 against standard chemotherapy in people with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. Participants are randomly assigned to receive either SYS6043 or one of three standard chemotherapies. The main goal is to see if SYS6043 can delay cancer progression better than current options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental antibody-drug conjugate called SYS6043
- What this could lead to
- If successful, SYS6043 could offer a new treatment option for people with platinum-resistant ovarian cancer, potentially slowing disease progression better than current chemotherapies.
- What could go wrong
- This is an early-phase 3 trial, so results are not yet known. The experimental drug may not prove more effective or safer than existing chemotherapies, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take on Hard-to-Treat ovarian and endometrial cancers
- New drug combo aims to prevent deadly bowel blockages in ovarian cancer
- New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
- New hope for Platinum-Resistant ovarian cancer: Rina-S trial launches
- Drug combo shows promise in early ovarian cancer trial
- New hope for ovarian cancer: drug combo targets resistant tumors